All In Biotech

Free tool

FAERS Monitor: Amyvid

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 202008 or its brand name (Amyvid, Florbetapir F-18). Reports on generic versions are filed under their own applications.

Reports

115

Serious

23

20% of reports

Hospitalization

12

Death reported

1

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • amyloid related imaging abnormality-oedema/effusion28
  • amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits27
  • headache14
  • superficial siderosis of central nervous system9
  • injection site pain7
  • chest pain4
  • fall4
  • fatigue4
  • nausea4
  • balance disorder3
  • burning sensation3
  • confusional state3
  • drug ineffective3
  • erythema3
  • false negative investigation result3

Reports by year received

View as table
YearReports
20131
20142
201515
20167
20175
20183
20192
20202
20212
20223
202345
20246
202518
20264

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,044 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
superficial siderosis of central nervous systemSignal913963.67270.1104,138
amyloid related imaging abnormality-microhaemorrhages and haemosiderin depositsSignal274725.73378.9119,775
amyloid related imaging abnormality-oedema/effusionSignal284264.73074.9112,516
false negative investigation resultSignal3784.6256.21,623
burning sensationSignal37.82.612
balance disorderSignal36.32.19
injection site painSignal74.22.014
headacheSignal144.12.531
chest painSignal44.01.56
confusional state33.41.13
erythema32.70.92
fall42.20.82
fatigue40.90.40
nausea40.90.40
drug ineffective30.40.12

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.